- Kincell Bio announces a multi-year partnership to produce patient-specific cell therapy batches at its Florida facility.
Kincell Bio, a cell therapy contract development and manufacturing organisation (CDMO), has entered into a new multi-year agreement with a clinical-stage cell therapy company. The partnership will focus on producing patient-specific batches of clinical-grade cell therapy products at Kincell’s facility in Gainesville, Florida.
The contract adds to Kincell Bio’s growing portfolio of cell therapy projects, further establishing the company as a trusted player in the industry. The Gainesville facility is GMP-ready and designed to meet the manufacturing needs of its clients’ clinical development plans.
Bruce Thompson, PhD, CEO of Kincell Bio, commented on the new partnership: “We’re delighted to welcome another client to our Gainesville facility. Our team thrives on providing critical CMC development and manufacturing expertise to support our clients’ clinical development plans to help patients.”
